[go: up one dir, main page]

EA201291089A1 - Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций - Google Patents

Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций

Info

Publication number
EA201291089A1
EA201291089A1 EA201291089A EA201291089A EA201291089A1 EA 201291089 A1 EA201291089 A1 EA 201291089A1 EA 201291089 A EA201291089 A EA 201291089A EA 201291089 A EA201291089 A EA 201291089A EA 201291089 A1 EA201291089 A1 EA 201291089A1
Authority
EA
Eurasian Patent Office
Prior art keywords
active ingredients
oral administration
pharmaceutical preparations
preparations intended
obtaining pharmaceutical
Prior art date
Application number
EA201291089A
Other languages
English (en)
Inventor
Акселль Лезо
Дамия Лейде
Арно Муссель
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42797556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201291089(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи filed Critical Санофи
Publication of EA201291089A1 publication Critical patent/EA201291089A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Paints Or Removers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к способу "термоплавкого покрытия" фармацевтически активных ингредиентов, отличающихся органолептическими или физико-химическими свойствами, которые желательно замаскировать. Изобретение также относится к конечным медицински активным ингредиентам с замаскированными органолептическими или физико-химическими свойствами и к содержащим их композициям.
EA201291089A 2010-04-21 2011-04-20 Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций EA201291089A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1053034A FR2959130A1 (fr) 2010-04-21 2010-04-21 Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
PCT/IB2011/051736 WO2011132167A1 (en) 2010-04-21 2011-04-20 Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same

Publications (1)

Publication Number Publication Date
EA201291089A1 true EA201291089A1 (ru) 2013-05-30

Family

ID=42797556

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201291089A EA201291089A1 (ru) 2010-04-21 2011-04-20 Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций
EA201291088A EA201291088A1 (ru) 2010-04-21 2011-04-20 Композиция на основе фексофенадина и способ ее получения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201291088A EA201291088A1 (ru) 2010-04-21 2011-04-20 Композиция на основе фексофенадина и способ ее получения

Country Status (23)

Country Link
US (2) US20130251794A1 (ru)
EP (2) EP2560612B1 (ru)
JP (2) JP2013525341A (ru)
KR (2) KR20130080428A (ru)
CN (2) CN103002874B (ru)
AR (2) AR081539A1 (ru)
AU (2) AU2011262319A1 (ru)
BR (2) BR112012026596A2 (ru)
CA (2) CA2796821A1 (ru)
CL (2) CL2012002898A1 (ru)
CO (2) CO6620042A2 (ru)
EA (2) EA201291089A1 (ru)
ES (2) ES2525163T3 (ru)
FR (1) FR2959130A1 (ru)
IL (2) IL222576A0 (ru)
MA (2) MA34226B1 (ru)
MX (1) MX2012012275A (ru)
PH (2) PH12012502084A1 (ru)
PL (2) PL2560613T3 (ru)
SG (3) SG10201506708UA (ru)
TW (2) TW201204415A (ru)
UY (2) UY33350A (ru)
WO (2) WO2011132167A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102349889B (zh) * 2011-11-01 2013-08-28 江苏先声药物研究有限公司 一种含有决奈达隆的组合物
JP5841433B2 (ja) * 2012-01-11 2016-01-13 日東電工株式会社 口腔内フィルム状基剤及び製剤
JP6245677B2 (ja) * 2012-01-20 2017-12-13 ニプロ株式会社 口腔内崩壊錠
JP6255908B2 (ja) * 2012-11-09 2018-01-10 大正製薬株式会社 固形製剤
FR2999937B1 (fr) 2012-12-21 2015-01-09 Sanofi Sa Unite solide a haute teneur en fexofenadine et son procede de preparation
CN104274408A (zh) * 2013-07-10 2015-01-14 北京科信必成医药科技发展有限公司 一种熔融包衣的速释药物微粒及其制备方法
CN103610645B (zh) * 2013-11-25 2016-05-11 浙江万晟药业有限公司 一种非索非那定盐酸盐的药物组合物及制备方法
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2016120299A1 (en) * 2015-01-28 2016-08-04 Sanovel Ilac Sanayi Ve Ticaret A.S. Orally disintegrating formulations of dronedarone
WO2017093890A1 (en) * 2015-11-30 2017-06-08 Piramal Enterprises Limited Clobazam tablet formulation and process for its preparation
EP3363429A1 (en) * 2017-02-20 2018-08-22 DSM IP Assets B.V. Process for the production of coated particles
EP3670489A1 (en) * 2018-12-21 2020-06-24 Dompé farmaceutici S.p.A. Co-crystal of ketoprofen, compositions comprising the same, process of producing the same, and uses thereof
EP4247331A1 (en) 2020-11-18 2023-09-27 BioPharma Synergies, S. L. Orodispersible powder composition comprising an antihistamine compound
WO2022175829A1 (en) * 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions
MX2024008242A (es) * 2021-12-29 2024-07-19 Opella Healthcare Group Sas Composiciones que contienen fexofenadina.

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL193682C (nl) 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
JPH07100665B2 (ja) * 1987-12-23 1995-11-01 信越化学工業株式会社 被覆薬剤の製造方法
US5296236A (en) * 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
US5578322A (en) * 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
WO1992009275A1 (en) * 1990-11-30 1992-06-11 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
WO1994008576A1 (en) * 1992-10-16 1994-04-28 Glaxo Group Limited Taste-masking compositions of ranitidine
DK0812195T3 (da) 1995-02-28 2003-03-03 Aventis Pharma Inc Farmaceutisk sammensætning til piperidinoalkanolforbindelser
US5846632A (en) * 1995-06-29 1998-12-08 Eastman Kodak Company Transfer support and method for fusing a transferrable image to a digital disc
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
FR2753904B1 (fr) * 1996-10-01 1998-10-30 Gattefosse Ets Sa Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication
US5891476A (en) * 1997-12-22 1999-04-06 Reo; Joe P. Tastemasked pharmaceutical system
US6274162B1 (en) * 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
FR2811912B1 (fr) * 2000-07-21 2003-02-07 Gattefosse Ets Sa Procede d'enrobage de particules solides par un agent thermofusible, et particules solides ainsi enrobees
UA80393C2 (ru) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтическая композиция, которая содержит ингибитор фдэ 4, диспергированный в матрице
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
FR2838647B1 (fr) * 2002-04-23 2006-02-17 Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant
AU2003259910A1 (en) * 2002-08-14 2004-03-03 E.I. Du Pont De Nemours And Company Process for coating a pharmaceutical particle
FR2848855B1 (fr) 2002-12-23 2005-02-11 Aventis Pharma Sa Compositions pour administration orale de principes actifs necessitant un masquage du gout
ATE341312T1 (de) * 2003-05-20 2006-10-15 Ethypharm Sa Orale pharmazeutische zusammensetzung mit verzögerter freisetzung
FR2857263B1 (fr) * 2003-07-09 2005-09-09 Sanofi Synthelabo Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
WO2005062722A2 (en) * 2003-11-21 2005-07-14 Sun Pharmaceutical Industries Limited Fexofenadine containing pharmaceutical formulation
WO2005065639A2 (en) * 2003-11-21 2005-07-21 Torrent Pharmaceuticals Limited Novel pharmaceutical compositions
EP1727524B1 (en) 2004-03-19 2009-10-21 Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Preparation of lipid coated cefuroxime axetil
US20070048373A1 (en) * 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods

Also Published As

Publication number Publication date
WO2011151733A3 (en) 2012-01-26
ES2525163T3 (es) 2014-12-18
JP2013525340A (ja) 2013-06-20
KR20130094716A (ko) 2013-08-26
KR20130080428A (ko) 2013-07-12
EP2560613B1 (en) 2014-10-15
IL222578A0 (en) 2012-12-31
CL2012002909A1 (es) 2013-01-25
US20130251794A1 (en) 2013-09-26
EP2560613A2 (en) 2013-02-27
CN103002874B (zh) 2015-04-08
CN102946857A (zh) 2013-02-27
CN103002874A (zh) 2013-03-27
AU2011244020A1 (en) 2012-11-08
TW201206434A (en) 2012-02-16
MX2012012275A (es) 2012-11-16
US20130183382A1 (en) 2013-07-18
PH12012502084A1 (en) 2013-02-04
CA2796816A1 (en) 2011-12-08
PH12012502085A1 (en) 2013-02-04
FR2959130A1 (fr) 2011-10-28
IL222576A0 (en) 2012-12-31
WO2011132167A1 (en) 2011-10-27
JP2013525341A (ja) 2013-06-20
TWI478713B (zh) 2015-04-01
SG10201506708UA (en) 2015-09-29
AR080934A1 (es) 2012-05-16
CL2012002898A1 (es) 2013-03-01
UY33350A (es) 2011-12-01
BR112012026938A2 (pt) 2017-10-03
SG184951A1 (en) 2012-11-29
BR112012026596A2 (pt) 2016-07-12
WO2011151733A2 (en) 2011-12-08
PL2560612T3 (pl) 2015-03-31
TW201204415A (en) 2012-02-01
PL2560613T3 (pl) 2015-03-31
CA2796821A1 (en) 2011-10-27
ES2527390T3 (es) 2015-01-23
EP2560612A1 (en) 2013-02-27
EA201291088A1 (ru) 2013-03-29
EP2560612B1 (en) 2014-09-03
UY33351A (es) 2011-12-01
SG184950A1 (en) 2012-11-29
AU2011262319A1 (en) 2012-11-08
CO6620043A2 (es) 2013-02-15
MA34227B1 (fr) 2013-05-02
AR081539A1 (es) 2012-10-03
MA34226B1 (fr) 2013-05-02
CO6620042A2 (es) 2013-02-15

Similar Documents

Publication Publication Date Title
EA201291089A1 (ru) Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций
PH12020550341A1 (en) Niraparib formulations
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
ATE517882T1 (de) Chinolinderivate
WO2012004706A3 (en) Chemical compounds
EA201291306A1 (ru) Состав сухого порошка, содержащий антимускариновое средство
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
EP3626253A3 (en) Stable formulations of linaclotide
EA201390409A1 (ru) Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием
WO2012007868A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
MX2019011491A (es) Formulaciones de niraparib.
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
EA201391018A1 (ru) Препараты иммуносупрессантов
IN2014MN00139A (ru)
WO2015038533A3 (en) Sodium channel modulators for the treatment of pain and diabetes
NZ607580A (en) N-heteroaryl compounds
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
EA201490166A1 (ru) Фторированные арилалкиламинокарбоксамидные производные
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
WO2010070152A3 (en) Use of dihydrodehydrodiisoeugenol and preparations comprising dihydrodehydrodiisoeugenol